<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628610</url>
  </required_header>
  <id_info>
    <org_study_id>Tisle-001</org_study_id>
    <nct_id>NCT05628610</nct_id>
  </id_info>
  <brief_title>Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer</brief_title>
  <official_title>Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the objective response rate (ORR) and safety of tislelizumab combined with&#xD;
      chemotherapy and Tislelizumab combined with radiotherapy in elderly patients with esophageal&#xD;
      cancer with advanced or recurrent metastasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical response of treatment according to RESIST v1.1 criteria (ORR, objective response rate).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>The length of time from enrollment until the time of progression of disease (PFS, progression-free survival).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Tislelizumab combined with radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tislelizumab combined with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>200mg d1, Q3W</description>
    <arm_group_label>Tislelizumab combined with chemotherapy</arm_group_label>
    <arm_group_label>Tislelizumab combined with radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Radiotherapy dose: 5,000 c G y / 30f</description>
    <arm_group_label>Tislelizumab combined with radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel: 150mg / m2 ,d1, q3w</description>
    <arm_group_label>Tislelizumab combined with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs</intervention_name>
    <description>cisplatin, carboplatin, naidaplatin and other platinum drugs</description>
    <arm_group_label>Tislelizumab combined with chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed a written informed consent and volunteered to join the study;&#xD;
&#xD;
          -  Patients with esophageal squamous cell carcinoma confirmed by pathological&#xD;
             histological and / or immunohistochemical examination or progressing after surgical&#xD;
             resection, (the 8th edition, 2017) with UICC / AJCC TNM stage cT4N0-2M0, c any TN3M0,&#xD;
             or c any T any NM1 (clinical stage IV);&#xD;
&#xD;
          -  Unresectable advanced, recurrent, or metastatic oesophageal SCC;&#xD;
&#xD;
          -  Age: 70 years old;&#xD;
&#xD;
          -  E CO G P S 0-2&#xD;
&#xD;
          -  Has not received any systemic antitumor treatment for esophageal cancer, including&#xD;
             radiotherapy, chemotherapy, targeted, immunotherapy, etc.;&#xD;
&#xD;
          -  At least one measurable lesion was present&#xD;
&#xD;
          -  Main organs have normal function, including:&#xD;
&#xD;
        A) Routine blood tests (no blood components, cell growth factors, whitening agents,&#xD;
        platelets, anemia drugs are allowed within 14 days before the first use of the study drug)&#xD;
        Leukocyte count was at 3.0109/L Neutrophil count was at 1.0109/L Platelet count was at&#xD;
        8,0109/L Hemoglobin was at 80 g / L b) Blood biochemical examination: Total bilirubin was&#xD;
        at 1.5 ULN ALT ≤ 2.5×ULN ，AST ≤2.5×ULN ， Serum creatinine of 1.5 ULN, or creatinine&#xD;
        clearance of 45 mL/min (Cocheroft-Gault formula, see Annex 2)&#xD;
&#xD;
        -The subjects had good compliance and cooperated with the follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There is uncontrollable pleural effusion, pericardial effusion or ascites that&#xD;
             requires repeated drainage;&#xD;
&#xD;
          -  Poor nutritional status, BMI &lt;18.5 Kg / m2; if corrected after symptomatic nutritional&#xD;
             support, further enrollment can be considered after evaluation by the principal&#xD;
             investigator;&#xD;
&#xD;
          -  Gastrointestinal bleeding (bleeding volume&gt; 200ml / day);&#xD;
&#xD;
          -  Patients adjudged by the researchers to have deep ulcers;&#xD;
&#xD;
          -  Previous history of allergy to monoclonal antibodies, any component of tirellizumab,&#xD;
             paclitaxel, cisplatin, or other platinum drugs;&#xD;
&#xD;
          -  Has received or are receiving any of the following treatments:&#xD;
&#xD;
        A) Any radiotherapy, chemotherapy, or other antitumor drugs directed against the tumor;&#xD;
        Study drug b) Treatment with immunosuppressive drugs or systemic hormones for&#xD;
        immunosuppression purposes within 2 weeks of the first study drug (dose or equivalent dose&gt;&#xD;
        10mg / day); inhaled or topical steroids and doses&gt; 10mg / day prednisone or equivalent&#xD;
        dose of adrenal corticoid replacement in the absence of active autoimmune disease; The c)&#xD;
        Acceptance of a live attenuated vaccine within 4 weeks before the first use of the study&#xD;
        drug; d) Major surgery or severe trauma within 4 weeks prior to the first use of the study&#xD;
        drug;&#xD;
&#xD;
          -  History of any active autoimmune or autoimmune disease, including but not limited to:&#xD;
             interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis,&#xD;
             hyperthyroidism, hypothyroidism (considered after HRT); patients with psoriasis or&#xD;
             asthma / allergy in childhood remission and adults without any intervention, but&#xD;
             patients requiring bronchodilator are not included;&#xD;
&#xD;
          -  A history of immunodeficiency, including positive HIV testing, or other acquired or&#xD;
             congenital immunodeficiency diseases, or a history of organ transplantation or&#xD;
             allogeneic bone marrow transplantation;&#xD;
&#xD;
          -  Poor clinical cardiac symptoms or disease, including but not limited to:&#xD;
&#xD;
        Such as (1) heart failure of grade NYHAII or above; (2) unstable angina pectoris; (3)&#xD;
        myocardial infarction within 1 year; (4) clinical significance of supraventricular or&#xD;
        ventricular arrhythmia without clinical intervention or clinical intervention is not well&#xD;
        controlled;&#xD;
&#xD;
          -  Severe infection (CTCAE&gt; 2) within 4 weeks before initial use of study drug, such as&#xD;
             severe pneumonia, bacteremia, or infection complications requiring hospitalization;&#xD;
             baseline chest imaging indicates active lung inflammation, symptoms or signs of&#xD;
             infection within 14 days prior to initial use of study drug, or requiring oral or&#xD;
             intravenous antibiotics, except for prophylactic antibiotics;&#xD;
&#xD;
          -  Patients with active tuberculosis infection by medical history or CT examination, or&#xD;
             active tuberculosis infection within 1 year prior to enrollment, or active&#xD;
             tuberculosis infection within 1 year before enrollment, or before enrollment but&#xD;
             without formal treatment;&#xD;
&#xD;
          -  The presence of active hepatitis B (HBV DNA 2000 IU / mL or 104 copies / mL),&#xD;
             hepatitis C (hepatitis C antibody positive, and HCV RNA above the lower limit of the&#xD;
             analysis method);&#xD;
&#xD;
          -  According to the investigator, there are other factors present that may lead to the&#xD;
             forced termination of the study, such as other serious illness (including mental&#xD;
             illness) requiring combined treatment, alcohol abuse, substance abuse, family or&#xD;
             social factors, that may affect the safety or compliance of the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 18, 2022</study_first_submitted>
  <study_first_submitted_qc>November 18, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2022</study_first_posted>
  <last_update_submitted>November 18, 2022</last_update_submitted>
  <last_update_submitted_qc>November 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

